But generally speaking, investors can have confidence in mega-cap stocks with a dominant position within their industry. As Silicon Valley entrepreneur Peter Thiel once wrote, "Competition is for ...
Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.
The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...
Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...
CAMBRIDGE, Mass. - Scholar Rock (NASDAQ: SRRK), a biopharmaceutical company with a market capitalization of $3.96 billion and an impressive 362.73% stock price surge over the past six months, ...
WASHINGTON (AP) — Robert F. Kennedy Jr.’s anti-vaccine advocacy is outside the mainstream. His previous statements on ...
A front-of-package food label would be a great educational tool. The Trump administration should keep it.
After 20 years of hemming, hawing, and “evaluating the science,” the FDA is finally muscling its way onto the most coveted ...
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Several years ago, a little-known drug named Ozempic—previously used only to treat diabetes—emerged as a promising new drug ...
The extent to which newer, incretin-based drugs for obesity improve disease outcomes via weight loss versus the direct ...
A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a ...